


10 RSC 11 FEB 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/500,521
Filing Date	June 30, 2004
First Named Inventor	Gideon Schreiber
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	05558.0018.PCUS00

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A4	Re 33,653	07-30-1991	Mark, et al.	
TS	A1	4,588,585	05-13-1986	Mark, et al.	
TS	A3	4,737,462	04-12-1988	Mark, et al.	
TS	A8	4,904,584	02-27-1990	Shaw	
TS	A2	4,959,314	09-25-1990	Mark, et al.	
TS	A6	4,965,195	10-23-1990	Namen, et al.	
TS	A7	5,017,691	05-21-1991	Lee, et al.	
TS	A5	5,116,943	05-26-1992	Koths, et al.	
	A9				
	A10				
	A11				
	A12				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
TS	B1	EP 0220 574	05-06-1987	Yeda Research and Development Company, Limited		
TS	B2	EP 0679717 B1	08-25-1999	Yeda Research and Development Company, Limited		
TS	B3	EP1037658 B1	06/05/2002	Applied Research Systetms ARS Holidng, N.V.		
TS	B4	WO 00/22146	04-20-2000	AMITAI		
TS	B5	WO 99/32141 A1	07/01/1999	Applied Research		

Examiner Signature		Date Considered	11/7/05
-----------------------	--	--------------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
DM_US8084656.v1

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/500,521	
			Filing Date	June 30, 2004	
			First Named Inventor	Gideon Schreiber	
			Group Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	1	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
195	C1	Alam, J., et al., "Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Beta-1a (IFNβ-1a) Products Administered Intramuscularly in Healthy Male and Female Volunteers", Pharmaceutical Research, Vol. 14, No. 4 (1997)	
	C2	Alan, R., et al., "Interferon αβ Selectively Antagonises Down-Regulation of Mannosyl-Fucosyl Receptors on Activated Macrophages by Interferon γ," Biochem. Biophys. Res. Commun., 136(2); pps. 737-744 (April 1986)	
195	C3	Anfinsen, C., "Principles that Govern the Folding of Protein Chains," Science, Vol. 181, No. 4096, July 20, 1973.	
195	C4	Baron, S., et al., "The Interferons: Mechanisms of Action and Clinical Applications," JAMA, Vol. 266, No. 10, pp. 1375-1383, September 11, 1991	
195	C5	Baron, S., et al., "The Interferons: a Biological System with Therapeutic Potential in Viral Infections," Antiviral Research, Vol. 24, pp. 97-110 (1994)	
195	C6	Chill, J., et al., "The Human Interferon Receptor: NMR-Based Modeling, Mapping of the IFN-α2 Binding Site, and Observed Ligand-Induced Tightening," Biochemistry, Vol. 41, pp. 3575-3585 (2002)	
195	C7	Christofinis, G., et al., "Interferon Production by Human Lymphoblastoid Cell Lines of Different Origins," J. Gen. Virol., Vol. 52, pp. 169-171 (1981)	
195	C8	Colamonici, O., et al., "Identification of a Novel Subunit of the Type I Interferon Receptor Localized to Human Chromosome 21," The Journal of Biological Chemistry, Vol. 268, No. 15, pp. 10895-10899, May 25, 1993	

Examiner Signature		Date Considered	11/7/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JS	C9	Colamonici, O., et al., "Multichain Structure of the IFN- α Receptor on Hematopoietic Cells," The Journal of Immunology, Vol. 148, No. 7, pp. 2126-2132, April 1, 1992	
JS	C10	Curtis, B., et al., "Enhanced Hematopoietic Activity of a Human Granulocyte/Macrophage Colony-Stimulating Factor-Interleukin 3 Fusion Protein," Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 5809-5813 (July 1991)	
JS	C11	Cusi, M., et al., "Harlequin Granulocyte-Colony Stimulating Factor Interleukin 6 Molecules with Bifunctional and Antagonistic Activities," Immunotechnology, Vol. 3, pp. 61-69 (1997)	
JS	C12	Domanski, P., et al., "Cloning and Expression of a Long Form of the β Subunit of the interferon $\alpha\beta$ Receptor That is Required for Signaling," The Journal of Biological Chemistry, Vol. 270, No. 37, pp. 21606-21611, September 15, 1995	
JS	C13	Dron et al., "Interferon $\alpha\beta$ Gene Structure and Regulation in Interferon: Principals and Medical Applications," Baron et al., Editors, University of Texas Medical Branch: Galveston, TX, pps. 33-45 (1992)	
JS	C14	Duncan, G., et al., "The Transcription Factor Interferon Regulatory Factor-1 Is Essential for Natural Killer Cell Function in Vivo," J. Exp. Med., Vol. 184, pp. 2043-2048 (November 1996)	
JS	C15	Edgington, S., "Biotech Products as Drug Leads", <u>Biotechnology</u> , Vol. 13, p. 649 (July 1995)	
JS	C16	Ezekowitz, R., et al., "Interferon α/β Selectively Antagonises Down-Regulation of Mannosyl-Fucosyl Receptors on Activated Macrophages by Interferon," Biochemical and Biophysical Research Communications, Vol. 136, No. 2, pp. 737-744, April 29, 1986	

Examiner Signature		Date Considered	11/7/05
---------------------------	---	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10 Rec'd EST/PTO 11 FEB 2005

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/500,521	
			Filing Date	June 30, 2004	
			First Named Inventor	Gideon Schreiber	
			Group Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	3	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JS	C17	Fierlbeck, G., et al., "Pharmacodynamics of Recombinant IFN- β During Long-Term Treatment of Malignant Melanoma," Journal of Interferon and Cytokine Research, Vol. 16, pp. 777-781 (1996)	
JS	C18	Grantham R., Amino Acid Difference Formula to Help Explain Protein Evolution," Science, Vol. 185, pp. 862-864, September 6, 1974	
JS	C19	Ibanez, C., et al., "Chimeric Molecules With Multiple Neurotrophic Activities Reveal Structural Elements Determining the Specificities of NGF and BDNF", The EMBO Journal., Vol. 10, No. 8, pp. 2105-2110 (1991)	
JS	C20	Jacobs, L., et al., "Intrathecaly Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis," Arch Neurol., Vol. 44, pp. 589-595 (June 1987)	
JS	C21	Keown, W., et al., "Methods for Introducing DNA into Mammalian Cells," Methods in Enzymology, Vol. 185, pp. 527-537 (1990)	
JS	C22	Lengyel, P., "Biochemistry of Interferons and Their Actions," Ann. Rev. Biochem., Vol. 51, pp. 251-282, (1982)	
JS	C23	Lewerenz, M., et al., "Shared Receptor Components but Distinct Complexes for α and β Interferons," J. Mol. Biol., Vol. 282, pp. 585-599 (1998)	
JS	C24	Lutfalla, G., "Mutant U5A Cells Are Complemented by an Interferon- $\alpha\beta$ Receptor Subunit Generated by Alternative Processing of a New Member of a Cytokine Receptor Gene Cluster", The EMBO Journal, Vol. 14, No. 20, pp. 5100-5108 (1995)	
JS	C25	Novick, D., et al., "Soluble Interferon- α Receptor Molecules are Present in Body Fluids," FEBS, Vol. 314, No. 3, pp. 445-448 (December 1992)	

Examiner Signature		Date Considered	11/7/05
---------------------------	---	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8084657.v1

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/500,521
		Filing Date	June 30, 2004
		First Named Inventor	Gideon Schreiber
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet	4	of	6
		Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JS	C26	Novick, D., et al., "Soluble and Membrane-Anchored Forms of the Human IFN- α/β Receptor," Journal of Leukocyte Biology, Vol. 57, pp. 712-718 (May 1995)	
JS	C27	Novick, D., et al., "The Human Interferon α/β Receptor: Characterization and Molecular Cloning," Cell, Vol. 77, pp. 391-400, May 6, 1994	
JS	C28	Olins, P., et al., "Recent Advances in Heterologous Gene Expression In <i>Escherichia Coli</i> ", Current Opinion in Biotechnology, Vol. 4 (5), pp. 520-525 (1993)	
JS	C29	Pestka, S., et al., "Interferons and Their Actions," Ann. Rev. Biochem., Vol. 56, pp. 727-777 (1987)	
JS	C30	Piebler, J., et al., "Mutational and Structural Analysis of the Binding Interface between Type I Interferons and their Receptor Ifnar2," J. Mol. Biol., Vol. 294, No. 1, pp. 223-237 (1999)	
JS	C31	Piebler, J., "Fast Transient Cytokine-Receptor Interactions Monitored in Real Time by Reflectometric Interference Spectroscopy," Analytical Biochemistry, Vol. 289, pp. 173-186 (2001)	
JS	C32	Piebler, J., et al., "Biophysical Analysis of the Interaction of Human Ifnar2 Expressed in <i>E. coli</i> with IFN α 2," J. Mol. Biology, Vol. 289, pp. 57-67 (1999)	
JS	C33	Platanias L., et al., "Differences in Interferon α and β Signaling," The Journal of Biological Chemistry, Vol. 271, No. 39, pp. 23630-23633, September 27, 1996	
JS	C34	Platanias, L., et al., "Characterization of the α Subunit of the IFN- α Receptor," The Journal of Immunology, Vol., 150, No. 8, pp. 3382-3388, April 15, 1993	

Examiner Signature		Date Considered	11/7/05
---------------------------	---	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO Rec'd 1/27/05

FEB 2005

PTO/SB/088 (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/500,521	
			Filing Date	June 30, 2004	
			First Named Inventor	Gideon Schreiber	
			Group Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	5	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JS	C35	Platanias, L., et al., "Tyrosine Phosphorylation of the α and β Subunits of the Type 1 Interferon Receptor," J. Biol. Chem. 269 (27): pps. 17761-17764 (July 1994)	
JS	C36	Qureshi, S., et al., "Function of Stat2 Protein in Transcriptional Activation by Alpha Interferon," Molecular and Cellular Biology, Vol. 16, No. 1, pp. 288-293 (Jan. 1996)	
JS	C37	Reff, Mitchell, "High-Level Production of Recombinant Immunoglobulins in Mammalian Cells," Current Opinion in Biotechnology, Vol. 4, pp. 573-576 (1993)	
JS	C38	Reuveny S., et al., "Effect of Temperature and Oxygen on Cell Growth and Recombinant Protein Production in Insect Cell Cultures," Appl. Microbiol. Biotechnol., Vol. 38, pp. 619-623 (1993)	
JS	C39	Roisman, L., et al., "Structure of the Interferon-Receptor Complex Determined by Distance Constraints from Double-Mutant Cycles and Flexible Docking," PNAS, Vol. 98, No. 23, pp. 13231-13236, November 6, 2001	
JS	C40	Rubenstein, D., et al., "Advances in the Treatment of Virus Diseases," Practitioner, 207 (240): pps. 510-515 (October 1971)	
JS	C41	Salmon, P., et al., "Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon- β in Healthy Male Volunteers," Journal of Interferon and Cytokine Research, Vol. 16, pp. 759-764 (1996)	
JS	C42	Sharf, R., et al., "Functional Domain Analysis of Interferon Consensus Sequence Binding Protein (ICSBP) and Its Association with Interferon Regulatory Factors," The Journal of Biological Chemistry, Vol. 270, No. 22, pp. 13063-13069, June 2, 1995	
JS	C44	Smith, G., et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Molecular and Cellular Biology, Vol. 3, No. 12, pp. 2156-2165 (Dec. 1983)	

Examiner Signature		Date Considered	11/7/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/500,521
		Filing Date	June 30, 2004
		First Named Inventor	Gideon Schreiber
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet	6	of	6
		Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JS	C45	Tan, Y., et al., "The Linkage of Genes for the Human Interferon-Induced Antiviral Protein and Indophenol Oxidase-B Traits to Chromosome G-21," Journal of Experimental Medicine, Vol. 137, pp. 317-330 (1973)	
JS	C46	Terlizzese, M., et al., "In Vitro Comparison of Inhibiting Ability of Soluble TNF Receptor p75 (TBP II) vs. Soluble TNF Receptor p 55 (TBP I) Against TNF- α and TNF- β ," Journal of Interferon and Cytokine Research, Vol. 16, No. 12, pp. 1047-1053 (1996)	
JS	C47	Utsumi, J., et al., "Characterization of <i>E. coli</i> -Derived Recombinant Human Interferon- β as Compared with Fibroblast Human Interferon- β ," J. Biochem., Vol. 101, No. 5, pp. 1199-1208 (1987)	
JS	C48	Uze, G., et al., "Genetic Transfer of a Functional Human Interferon α Receptor into Mouse Cells: Cloning and Expression of Its cDNA," Cell, Vol. 60, pp. 225-234, January 26, 1990	
JS	C49	Weismann, et al., "Structure and Expression of Human Alpha-Interferon Genes," Princess Takamatsu Symp., Vol. 12, pps. 1-22 (1982)	
JS	C50	Yan, H., et al., "Molecular Characterization of an Alpha Interferon Receptor 1 Subunit (IFNaR1) Domain Required for TYK2 Binding and Signal Transduction," Molecular and Cellular Biology, Vol. 16, No. 5, pp. 2074-2082 (May 1996)	
JS	C51	Yang, C., et al., "Direct Association of STAT3 with IFNAR-1 Chain of the Human Type I Interferon Receptor," The Journal of Biological Chemistry, Vol. 271, No. 14., pp. 8057-8061, April 5, 1996	

Examiner Signature		Date Considered	11/7/05
---------------------------	---	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citations in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.